Login Register Cart 0
Generic placeholder image

Current Vascular Pharmacology

Editor-in-Chief

ISSN (Print): 1570-1611
ISSN (Online): 1875-6212

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Editorial

Which Statin is Best for the Kidneys?

Author(s): Peter E. Penson*, Maciej Banach and Alice P. McCloskey

Volume 21, Issue 1, 2023

Published on: 09 December, 2022

Page: [1 - 3] Pages: 3

DOI: 10.2174/1570161121666221202154440

Price: $65

Next »
[1]
Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 2016; 388(10059): 2532-61.
[http://dx.doi.org/10.1016/S0140-6736(16)31357-5] [PMID: 27616593]
[2]
Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J 2017; 38(32): 2459-72.
[http://dx.doi.org/10.1093/eurheartj/ehx144] [PMID: 28444290]
[3]
Penson PE, Pirro M, Banach M. LDL-C: lower is better for longer—even at low risk. BMC Med 2020; 18(1): 320.
[http://dx.doi.org/10.1186/s12916-020-01792-7] [PMID: 33032586]
[4]
Bytyçi I, Penson PE, Mikhailidis DP, et al. Prevalence of statin intolerance: a meta-analysis. Eur Heart J 2022; 43(34): 3213-23.
[http://dx.doi.org/10.1093/eurheartj/ehac015] [PMID: 35169843]
[5]
McCloskey AP, Penson PE, Tse Y, Abdelhafiz MA, Ahmed SN, Lim EJ. Identifying and addressing pill aversion in adults without physiological‐related dysphagia: A narrative review. Br J Clin Pharmacol 2022. bcp.15463.
[http://dx.doi.org/10.1111/bcp.15463] [PMID: 35849849]
[6]
Shin JI, Fine DM, Sang Y, et al. Association of rosuvastatin use with risk of hematuria and proteinuria. J Am Soc Nephrol 2022; 33(9): 1767-77.
[http://dx.doi.org/10.1681/ASN.2022020135] [PMID: 35853713]
[7]
Gluba A, Rysz J, Banach M. Statins in patients with chronic kidney disease: why, who and when? Expert Opin Pharmacother 2010; 11(16): 2665-74.
[http://dx.doi.org/10.1517/14656566.2010.512419] [PMID: 20977401]
[8]
The US Food and Drug Administration. Highlights of prescribing information for Crestor (rosuvastatin calcium) tablets. 2010. Available from: https://wwwaccessdatafdagov/drugsatfda_docs/label/2010/021366s016lblpdf.
[9]
Hill AB. The environment and disease: Association or causation? Proc R Soc Med 1965; 58(5): 295-300.
[http://dx.doi.org/10.1177/003591576505800503] [PMID: 14283879]
[10]
Vogt L, Bangalore S, Fayyad R, et al. Atorvastatin has a dose‐dependent beneficial effect on kidney function and associated cardiovascular outcomes: Post hoc analysis of 6 double‐blind randomized controlled trials. J Am Heart Assoc 2019; 8(9): e010827.
[http://dx.doi.org/10.1161/JAHA.118.010827] [PMID: 31020900]
[11]
Esmeijer K, Dekkers OM, de Fijter JW, Dekker FW, Hoogeveen EK. Effect of different types of statins on kidney function decline and proteinuria: a network meta-analysis. Sci Rep 2019; 9(1): 16632.
[http://dx.doi.org/10.1038/s41598-019-53064-x] [PMID: 31719617]
[12]
Banach M, Burchardt P, Chlebus K, et al. PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021. Arch Med Sci 2021; 17(6): 1447-547.
[http://dx.doi.org/10.5114/aoms/141941] [PMID: 34900032]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy